Abcuro: Funding, Investors & Team (Nov 2026)
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.
Abcuro has raised $147M across 3 funding rounds on record, the most recent a Series D of $66.0M announced in Aug 2026.
That round is above the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Abcuro Company Profile and Key Stats
Latest funding round on record: Aug 2026.
Abcuro Funding Rounds
Abcuro raised $42.0M in a Series A announced in Jan 2021.
5.6 years later, an undisclosed round of $39.4M was announced in Aug 2026.
A Series D of $66.0M was announced in Aug 2026.
Abcuro Investors
24 investors are recorded in total; the 5 named above are those the record identifies.
Abcuro Founders and Leadership Team
Contact details for the Abcuro team: 3 of 3 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Abcuro Funding Compared to Other Biotechnology Startups
Abcuro's latest round of $66.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Abcuro in Biotechnology and Newton
Companies Similar to Abcuro
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Abcuro Funding FAQs
What does Abcuro do?
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.
How much funding has Abcuro raised?
Abcuro has raised $147M across 3 rounds on record. The most recent is a Series D of $66.0M announced in Aug 2026.
When did Abcuro last raise funding?
Abcuro's most recent funding round on record is a Series D of $66.0M, announced in Aug 2026.
Who has invested in Abcuro?
Investors on record for Abcuro include RA Capital Management, BlackRock, New Enterprise Associates, Soleus Capital, Foresite Capital. FundedIQ records 24 investors in total.
Who is the CEO of Abcuro?
Alex Martin is listed as Active Chairman, CEO, and Life Coach at Abcuro.
Where is Abcuro headquartered?
Abcuro is based in Newton, Massachusetts, United States.
How many employees does Abcuro have?
Abcuro is in the 11-50 employee band.
When was Abcuro founded?
Abcuro was founded in 2015.
How does Abcuro's funding compare to other Biotechnology startups?
Abcuro's latest round of $66.0M is above the $8.8M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Abcuro Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Abcuro is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.